JP2014510114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510114A5 JP2014510114A5 JP2014502963A JP2014502963A JP2014510114A5 JP 2014510114 A5 JP2014510114 A5 JP 2014510114A5 JP 2014502963 A JP2014502963 A JP 2014502963A JP 2014502963 A JP2014502963 A JP 2014502963A JP 2014510114 A5 JP2014510114 A5 JP 2014510114A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- compound according
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 230000005494 condensation Effects 0.000 claims 2
- 238000009833 condensation Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- -1 1-ii Substances 0.000 claims 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000038012 SFKs Human genes 0.000 claims 1
- 108091008118 SFKs Proteins 0.000 claims 1
- 102000000551 Syk Kinase Human genes 0.000 claims 1
- 108010016672 Syk Kinase Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 *C(*CC1=O)C1C#N Chemical compound *C(*CC1=O)C1C#N 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471322P | 2011-04-04 | 2011-04-04 | |
| US61/471,322 | 2011-04-04 | ||
| CA2760174A CA2760174A1 (en) | 2011-12-01 | 2011-12-01 | Protein kinase inhibitors and uses thereof |
| CA2,760,174 | 2011-12-01 | ||
| PCT/CA2012/000333 WO2012135944A1 (en) | 2011-04-04 | 2012-04-03 | Protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510114A JP2014510114A (ja) | 2014-04-24 |
| JP2014510114A5 true JP2014510114A5 (https=) | 2015-05-21 |
| JP6001053B2 JP6001053B2 (ja) | 2016-10-05 |
Family
ID=46968500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502963A Expired - Fee Related JP6001053B2 (ja) | 2011-04-04 | 2012-04-03 | タンパク質キナーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9624239B2 (https=) |
| EP (1) | EP2694517A4 (https=) |
| JP (1) | JP6001053B2 (https=) |
| CA (2) | CA2760174A1 (https=) |
| WO (1) | WO2012135944A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140021629A (ko) * | 2011-04-04 | 2014-02-20 | 파마사이언스 인크. | 단백질 키나제 저해제 |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| CN105979948A (zh) | 2013-12-05 | 2016-09-28 | 安塞塔制药公司 | Pi3k抑制剂和btk抑制剂的治疗组合 |
| JP6301474B2 (ja) * | 2013-12-31 | 2018-03-28 | ジン，ボハン | 癌および炎症性疾患を処置するための新規化合物 |
| US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
| TW201618774A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
| TW201618775A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物 |
| PL3179991T3 (pl) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| EP3747472B1 (en) | 2015-09-15 | 2024-04-03 | Acerta Pharma B.V. | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor |
| DK3402503T3 (da) | 2016-01-13 | 2020-12-21 | Acerta Pharma Bv | Terapeutiske kombinationer af et antifolat og en btk-hæmmer |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| IL292938A (en) | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combined treatment |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| WO2023077216A1 (en) * | 2021-11-02 | 2023-05-11 | Bright Angel Therapeutics Inc. | Heat shock protein 90 (hsp90) inhibitors for treating fungal infections and methods of use thereof |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH643228A5 (en) * | 1979-02-02 | 1984-05-30 | Givaudan & Cie Sa | Process for the preparation of alpha-hydroxycarbonyl compounds |
| EP0738717A1 (en) | 1990-10-09 | 1996-10-23 | Neurogen Corporation | Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines |
| JP3465827B2 (ja) * | 1993-02-24 | 2003-11-10 | 株式会社日清製粉グループ本社 | アザインドール誘導体およびこれを有効成分とする抗潰瘍薬 |
| DE59500788D1 (de) * | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| GB9524346D0 (en) * | 1995-11-29 | 1996-01-31 | Univ Strathclyde | Polycyclic compounds |
| AU3176297A (en) * | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| CA2569016C (en) * | 2004-06-02 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US7982035B2 (en) | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| KR20140021629A (ko) * | 2011-04-04 | 2014-02-20 | 파마사이언스 인크. | 단백질 키나제 저해제 |
-
2011
- 2011-12-01 CA CA2760174A patent/CA2760174A1/en not_active Abandoned
-
2012
- 2012-04-03 WO PCT/CA2012/000333 patent/WO2012135944A1/en not_active Ceased
- 2012-04-03 US US14/009,635 patent/US9624239B2/en not_active Expired - Fee Related
- 2012-04-03 JP JP2014502963A patent/JP6001053B2/ja not_active Expired - Fee Related
- 2012-04-03 EP EP12767413.3A patent/EP2694517A4/en not_active Withdrawn
- 2012-04-03 CA CA2831813A patent/CA2831813A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510114A5 (https=) | ||
| Guillon et al. | New ferrocenic pyrrolo [1, 2-a] quinoxaline derivatives: Synthesis, and in vitro antimalarial activity–Part II | |
| JP2013508373A5 (https=) | ||
| JP2013504593A5 (https=) | ||
| JP2017523124A5 (https=) | ||
| JP2015042636A5 (ja) | 有機化合物 | |
| RU2013147400A (ru) | Способ получения производных кето-бензофурана | |
| Lavrado et al. | Incorporation of basic side chains into cryptolepine scaffold: Structure− antimalarial activity relationships and mechanistic studies | |
| RU2014110400A (ru) | Способ и промежуточные соединения для получения макролактамов | |
| JP2010513498A5 (https=) | ||
| JP2011037841A5 (https=) | ||
| RU2013124812A (ru) | Зонд, визуализирующий белок тау | |
| RU2013125326A (ru) | Гетероциклические соединения в качестве зондов для визуализации tau-патологии | |
| JP2016527345A5 (https=) | ||
| CA2330798C (en) | Febrifugine, isofebrifugine and method for producing the same | |
| Maiti et al. | Iodine/CuI-mediated alkyne–carbonyl metathesis reaction: synthesis of 1-aryl-1, 2-dihydrochromeno [2, 3-b] azepine-3, 6-dione | |
| AR045447A1 (es) | Compuestos triciclicos inhibidores de transferasa de proteina de farnesilo novedosos como agentes antitumorales | |
| JP2018505179A5 (https=) | ||
| AR046617A1 (es) | Compuestos inhibidores de selectina | |
| JP2013525473A5 (https=) | ||
| JP2011515441A5 (https=) | ||
| JP2017101118A5 (https=) | ||
| JP7301259B2 (ja) | 蛍光化合物及びそれを用いたオートファジー検出試薬 | |
| JP2014009330A5 (https=) | ||
| JP2008545624A5 (https=) |